2 results  1 of 1 

1 Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30–Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial
Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Hye Jin Kang, Hye Won Lee, Hyeon-Seok Eom, Jung Yong Hong, Junhun Cho, Young Hyeh Ko, Jooryung Huh, Woo-Ick Yang, Weon Seo Park, Seung-Sook Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat.2020;52(2):374-387.   Published online 2019 August 13     DOI: http://dx.doi.org/10.4143/crt.2019.198
      
2 Brentuximab vedotin: clinical updates and practical guidance
Jun Ho Yi, Seok Jin Kim, Won Seog Kim
Blood Res.2017;52(4):243-253.   Published online 2017 December 26     DOI: http://dx.doi.org/10.5045/br.2017.52.4.243
      

 1 of 1